Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 2/20 | 0.34 |
| ▸ | BRAF | P15056 | 10/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3388858 | 0.87 | MAPK14 (0.37) | MAPK14MAPK12MAPK13MAPK11GSK3A | |
| SCHEMBL3170645 | 0.85 | MAPK14 (0.49) | MAPK14MAPK12MAPK13MAPK11GSK3A | |
| SCHEMBL2953750 | 0.84 | MAPK14 (0.40) | MAPK14MAPK12MAPK13MAPK11PTK2B | |
| SCHEMBL13528641 | 0.84 | MAPK14 (0.52) | MAPK14MAPK12MAPK13MAPK11BRAF | |
| SCHEMBL3180417 | 0.83 | MAPK14 (0.37) | MAPK14MAPK12MAPK13MAPK11GSK3A | |
| SCHEMBL3392522 | 0.83 | MAPK14 (0.36) | MAPK14MAPK12MAPK13MAPK11GSK3A | |
| SCHEMBL3180405 | 0.81 | MAPK14 (0.43) | MAPK14MAPK12MAPK13MAPK11GSK3A | |
| SCHEMBL3392519 | 0.80 | MAPK14 (0.43) | MAPK14MAPK12MAPK13MAPK11GSK3A | |
| SCHEMBL3388916 | 0.80 | MAPK14 (0.38) | MAPK14MAPK12MAPK13MAPK11GSK3A | |
| SCHEMBL3394279 | 0.80 | MALT1 (0.37) | MAPK14MAPK12MAPK13MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943243-B1 | KINASE INHIBITORS | LILLY CO ELI (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7652015-B2 | Suppression cytokines , tumor necrosis factor | ELI LILLY AND COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080269244-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269244-A1 | Kinase Inhibitors | MAP3K1, MAP3K20, MAP3K19 | MAPK14 58/4885MAPK12 78/4885MAPK13 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.